KPTI

Karyopharm Therapeutics Inc. KPTI

$9.51 +0.13 (+1.39%)

Neutral · -0.26σ

+ Compare Open in Sniper

Price chart

Timeframe

Range

Loading…

Latest bar · KPTI

Momentum reads · latest daily bar

Last

$9.51

+0.13 (+1.39%)

Mkt cap

$216M

Healthcare

RSI(14)

48.9

neutral

Stochastic %K

19.2

oversold

MFI(14)

34.8

neutral

ADX(14)

32.0

trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

Quarter	Revenue	Net income	Op income	FCF	Net margin	Op margin
2026-03-31	$0.0B	$-0.0B	$-0.0B	$-0.0B	-63.9%	-76.3%
2025-12-31	$0.0B	$-0.1B	$-0.0B	$-0.0B	-299.9%	-52.4%
2025-09-30	$0.0B	$-0.0B	$-0.0B	$-0.0B	-75.2%	-34.6%
2025-06-30	$0.0B	$-0.0B	$-0.0B	$-0.0B	-98.2%	-64.3%
2025-03-31	$0.0B	$-0.0B	$-0.0B	$-0.0B	-78.2%	-110.8%
2024-12-31	$nanB	$nanB	$nanB	$nanB	nan%	nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare KPTI vs peers

Line KPTI up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing KPTI UNH× PFE×

Sector peers + LLY + JNJ + MRK + ABBV + TMO

Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO

Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Verdict

Weighted score 0-100 across 3 tickers · best in green

KPTI

score 63.3

5/5 inputs

Perfect growth score of 100 from 16.8% revenue expansion propels rank despite zero quality rating.

value 65growth 100quality 0momentum 60sentiment 67

UNH

score 65.5

5/5 inputs

Momentum dominates at 96 with 34.67% three-month gain offsetting mediocre 50 growth score.

value 48growth 50quality 80momentum 96sentiment 66

PFE

score 30.0

5/5 inputs

Catastrophic momentum score of 3 from negative returns across all periods sinks overall ranking.

value 49growth 15quality 65momentum 3sentiment 25

Metric	KPTI Karyopharm Therapeutics Inc.	UNH UnitedHealth Group Incorporated	PFE PFE
Snapshot
Price	9.51	426.09	25.05
Day %↕	1.39	0.64	-0.36
1M %↕	4.51	4.52	-3.8
3M %↕	9.82	34.67	-7.97
YTD %↕	32.27	26.66	-0.52
Market cap	215524608.0	386951249920.0	142771077120.0
ADV ($)	4308543.643695831	3118003879.2817383	1037779234.0927048
Beta	0.807	0.633	0.307
OdysseyHQ zone
Current zone	Neutral	Neutral	Neutral
Dist 21-EMA %	-1.73	1.78	1.53
Dist ATR (σ)	-0.26	0.6	0.7
OdysseyHQ grade	—	C	—
Confluence↕	2	3	0
Valuation
P/E (ttm)↕	—	32.060947	19.122137
P/E (fwd)↕	-1.9447854	19.240608	8.8405
P/S↕	1.4262007	0.85964525	2.2549329
EV/EBITDA↕	-5.095	17.696	7.648
P/B↕	-0.807095	3.9526708	1.5844401
FCF yield↕	-0.1128	0.0588	0.0867
PEG↕	—	1.42	2.96
Growth
Revenue yoy↕	0.168	0.004	0.054
EPS yoy↕	—	0.615	-0.101
FCF yoy↕	—	—	—
Revenue trend 8Q
Quality
Gross margin↕	0.13452	0.19514	0.74801004
Operating margin↕	-0.76313	0.071329996	0.31617
Net margin↕	-1.2901801	0.03137	0.118310004
ROE↕	—	0.14152999	0.083100006
ROA↕	-0.40622002	0.04382	0.05687
Debt / Equity↕	—	0.69	0.72
Interest cov.↕	-3.27	4.67	3.82
Technicals
RSI(14)	48.9	57.9	53.6
MACD signal	neutral	neutral	neutral
vs 50-DMA	3.69	5.76	-0.88
vs 200-DMA	25.19	24.8	-3.23
vs 52w high	-13.47	-7.7	-12.87
HV-30	62.3	26.9	23.5
Sentiment
Analyst rec↕	1.57143	1.59259	2.46429
Target upside↕	41.96	10.69	14.92
Insider buy-sell 90d↕	5	23	16
Risk
Short interest↕	29.2	2.26	2.87
Days to cover↕	12.59	2.55	3.45
Next earnings	2026-08-11	2026-07-16	2026-08-04

KPTI

Karyopharm Therapeutics Inc.

$9.51

+1.39%

Snapshot

Price 9.51

Day % 1.39

1M % 4.51

3M % 9.82

YTD % 32.27

Market cap 215524608.0

ADV ($) 4308543.643695831

Beta 0.807

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % -1.73

Dist ATR (σ) -0.26

OdysseyHQ grade —

Confluence 2

Valuation

P/E (ttm) —

P/E (fwd) -1.9447854

P/S 1.4262007

EV/EBITDA -5.095

P/B -0.807095

FCF yield -0.1128

PEG —

Growth

Revenue yoy 0.168

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.13452

Operating margin -0.76313

Net margin -1.2901801

ROE —

ROA -0.40622002

Debt / Equity —

Interest cov. -3.27

Technicals

RSI(14) 48.9

MACD signal neutral

vs 50-DMA 3.69

vs 200-DMA 25.19

vs 52w high -13.47

HV-30 62.3

Sentiment

Analyst rec 1.57143

Target upside 41.96

Insider buy-sell 90d 5

Risk

Short interest 29.2

Days to cover 12.59

Next earnings 2026-08-11

Full KPTI dashboard →

UNH

UnitedHealth Group Incorporated

$426.09

+0.64%

Snapshot

Price 426.09

Day % 0.64

1M % 4.52

3M % 34.67

YTD % 26.66

Market cap 386951249920.0

ADV ($) 3118003879.2817383

Beta 0.633

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % 1.78

Dist ATR (σ) 0.6

OdysseyHQ grade C

Confluence 3

Valuation

P/E (ttm) 32.060947

P/E (fwd) 19.240608

P/S 0.85964525

EV/EBITDA 17.696

P/B 3.9526708

FCF yield 0.0588

PEG 1.42

Growth

Revenue yoy 0.004

EPS yoy 0.615

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.19514

Operating margin 0.071329996

Net margin 0.03137

ROE 0.14152999

ROA 0.04382

Debt / Equity 0.69

Interest cov. 4.67

Technicals

RSI(14) 57.9

MACD signal neutral

vs 50-DMA 5.76

vs 200-DMA 24.8

vs 52w high -7.7

HV-30 26.9

Sentiment

Analyst rec 1.59259

Target upside 10.69

Insider buy-sell 90d 23

Risk

Short interest 2.26

Days to cover 2.55

Next earnings 2026-07-16

Full UNH dashboard →

PFE

$25.05

-0.36%

Snapshot

Price 25.05

Day % -0.36

1M % -3.8

3M % -7.97

YTD % -0.52

Market cap 142771077120.0

ADV ($) 1037779234.0927048

Beta 0.307

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % 1.53

Dist ATR (σ) 0.7

OdysseyHQ grade —

Confluence 0

Valuation

P/E (ttm) 19.122137

P/E (fwd) 8.8405

P/S 2.2549329

EV/EBITDA 7.648

P/B 1.5844401

FCF yield 0.0867

PEG 2.96

Growth

Revenue yoy 0.054

EPS yoy -0.101

FCF yoy —

Revenue trend 8Q

Quality

Gross margin 0.74801004

Operating margin 0.31617

Net margin 0.118310004

ROE 0.083100006

ROA 0.05687

Debt / Equity 0.72

Interest cov. 3.82

Technicals

RSI(14) 53.6

MACD signal neutral

vs 50-DMA -0.88

vs 200-DMA -3.23

vs 52w high -12.87

HV-30 23.5

Sentiment

Analyst rec 2.46429

Target upside 14.92

Insider buy-sell 90d 16

Risk

Short interest 2.87

Days to cover 3.45

Next earnings 2026-08-04

Full PFE dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

Date	EPS actual	EPS est	Surprise	Next-day
2026-05-14	-1.24	-1.44	+14.1%	-13.8%
2026-02-12	-2.23	-2.00	-11.3%	-4.0%
2025-11-03	-3.82	-3.25	-17.5%	-6.9%
2025-08-11	-4.07	-3.91	-4.0%	+6.6%
2025-05-12	-2.77	-3.09	+10.3%	-20.0%
2025-02-19	-3.60	-4.03	+10.7%	+1.7%
2024-11-05	-3.90	-3.92	+0.6%	+4.8%
2024-08-06	-4.34	-4.47	+2.8%	-3.5%
2024-05-08	-4.80	-4.94	+2.9%	+4.9%
2024-02-29	-5.40	-4.65	-16.2%	+2.2%
2023-11-02	-4.50	-4.29	-5.0%	+16.9%
2023-08-02	-4.35	-5.04	+13.8%	+1.1%
2023-05-04	-4.50	-5.23	+13.9%	-2.2%
2023-02-15	-6.45	-5.38	-19.9%	-1.9%
2022-11-03	-6.75	-8.02	+15.9%	+4.4%
2022-08-04	-9.30	-9.55	+2.6%	+3.3%
2022-05-05	-7.95	-9.24	+14.0%	-9.8%
2022-02-08	6.90	-6.37	+208.4%	+10.6%
2021-11-03	-10.35	-10.27	-0.8%	+0.4%
2021-08-05	-10.65	-10.97	+2.9%	-6.9%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅	Mkt cap ⇅	P/E ⇅	Fwd P/E ⇅	P/S ⇅	EV/EBITDA ⇅	P/B ⇅	Gross M ⇅	Rev gr ⇅	EPS gr ⇅	FCF yld ⇅
KPTI ★	$0B	—	-1.9	1.4	-5.1	-0.8	13.5%	16.8%	—	-11.28%
LLY	$1,051B	41.8	26.3	14.6	30.1	33.8	82.8%	55.5%	169.9%	0.87%
UNH	$387B	32.1	19.2	0.9	17.7	4.0	19.5%	0.4%	61.5%	5.88%
JNJ	$609B	29.3	19.7	6.2	18.4	7.5	68.1%	6.6%	-1.0%	—
MRK	$315B	36.0	13.2	4.8	12.1	6.9	76.7%	4.9%	—	4.46%
ABBV	$450B	124.8	15.6	7.2	17.2	-67.6	72.0%	12.4%	-46.2%	4.63%
PFE	$143B	19.1	8.8	2.3	7.6	1.6	74.8%	5.4%	-10.1%	8.67%
TMO	$198B	29.2	19.5	4.4	21.1	3.8	40.9%	6.2%	11.3%	2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 50.73%

Holder	Shares	% out
Commodore Capital Lp	1,950,000	8.60%
RA Capital Management, L.P.	1,917,354	8.46%
Adage Capital Partners GP L.L.C.	1,806,322	7.97%
T. Rowe Price Investment Management,	1,542,090	6.80%
Goldman Sachs Group Inc	947,579	4.18%
Catalio Capital Management, LP	897,709	3.96%
Vanguard Capital Management LLC	739,745	3.26%
Ikarian Capital, LLC	733,435	3.24%
Affinity Asset Advisors, Llc	500,000	2.21%
Avidity Partners Management, LP	463,741	2.05%

Insider activity · 90d

9 buys / 6 sells · ratio 1.5 · Finnhub

Su Zhen BUY 15,508
Oliger Christy J. BUY 15,508
Schor Chen BUY 15,508
Greene Barry E BUY 16,415
PAKIANATHAN DEEPIKA BUY 15,508
BOHLIN GAREN G BUY 18,517
Poulton Stuart SELL 94,821 @ $9.50
Rangwala Reshma SELL 56,829 @ $9.50
Cheng Sohanya Roshan SELL 107,940 @ $9.50
Abate Kristin SELL 23,801 @ $9.50

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low

$7.0

Mean

$13.5

High

$16.0

Analysts

Recommendation distribution · period 2026-07-01

Revision trend (2026-04-01 → 2026-07-01): net 11 → 11 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

Form	Filed	Description	Action
8-K	2026-07-17	8-K	view ·
8-K	2026-05-28	8-K	view ·
4	2026-05-26	4	view ·
4	2026-05-26	4	view ·
4	2026-05-26	4	view ·
4	2026-05-26	4	view ·
4	2026-05-26	4	view ·
4	2026-05-26	4	view ·
4	2026-05-15	4	view ·
4	2026-05-15	4	view ·
4	2026-05-15	4	view ·
4	2026-05-15	4	view ·
4	2026-05-15	4	view ·
4	2026-05-15	4	view ·
10-Q	2026-05-14	10-Q	view ·
8-K	2026-05-14	8-K	view ·
4	2026-04-22	4	view ·
DEF 14A	2026-04-13	DEF 14A	view ·
8-K	2026-03-27	8-K	view ·
8-K	2026-03-24	8-K	view ·
4	2026-03-03	4	view ·
4	2026-03-03	4	view ·
4	2026-03-03	4	view ·
4	2026-03-03	4	view ·
4	2026-03-03	4	view ·
4	2026-03-03	4	view ·
8-K	2026-03-03	8-K	view ·
8-K	2026-02-19	8-K	view ·
4	2026-02-19	4	view ·
10-K	2026-02-13	10-K	view ·
8-K	2026-02-12	8-K	view ·
4	2026-02-09	4	view ·
4	2026-02-04	4	view ·
4	2026-02-03	4	view ·
4	2026-02-03	4	view ·
4	2026-02-03	4	view ·
4	2026-02-03	4	view ·
4	2026-02-03	4	view ·
4	2026-01-29	4	view ·
4	2026-01-22	4	view ·
8-K	2026-01-12	8-K	view ·
DEF 14A	2026-01-09	DEF 14A	view ·
10-Q	2025-11-03	10-Q	view ·
8-K	2025-11-03	8-K	view ·
4	2025-10-16	4	view ·
4	2025-10-16	4	view ·
4	2025-10-16	4	view ·
4	2025-10-16	4	view ·
4	2025-10-16	4	view ·
4	2025-10-16	4	view ·
8-K	2025-10-14	8-K	view ·
8-K	2025-10-08	8-K	view ·
4	2025-10-03	4	view ·
4	2025-09-16	4	view ·
4	2025-09-16	4	view ·
4	2025-09-16	4	view ·
4	2025-09-16	4	view ·
4	2025-09-16	4	view ·
4	2025-09-16	4	view ·
8-K	2025-09-11	8-K	view ·

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene …

Options picks · KPTI

ITM + OTM ideas from the latest scan

Loading…

Congress trades · KPTI

STOCK Act disclosures

Loading…

SEC filings & insiders · KPTI

EDGAR · live

Loading…

Holders · KPTI

Institutions & insider activity

Loading…

Karyopharm Therapeutics Inc. KPTI

Price chart

Latest bar · KPTI

Financial overlay · last 12 quarters

Compare KPTI vs peers

Earnings replay · last 20 reports

Peer comparison · Healthcare

Ownership

Top institutional holders

Insider activity · 90d

Analyst estimates

SEC filings

About KPTI

Options picks · KPTI

Congress trades · KPTI

SEC filings & insiders · KPTI

Holders · KPTI

Filing summary